This week, we'll explore the latest clinical guidelines on pulmonary tuberculosis (TB), a contagious bacterial infection primarily affecting the lungs. Diagnostic methods such as Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs) serve as cornerstones for TB screening, with positive results indicating exposure to TB. Chest X-rays and CT scans aid in detecting pulmonary abnormalities suggestive of TB, such as cavitations, nodules, and infiltrates, while molecular tests like GeneXpert MTB/RIF assay provide rapid detection of Mycobacterium tuberculosis and rifampin resistance, guiding treatment decisions.
Recognizing TB symptoms promptly is crucial for initiating treatment and preventing transmission. Persistent cough, often with hemoptysis (coughing up blood), is a hallmark symptom of pulmonary TB, along with fever, night sweats, weight loss, and fatigue. Treatment strategies often involve Directly Observed Therapy (DOT) to ensure adherence to medication regimens, reducing the risk of drug resistance. The standard treatment for drug-susceptible pulmonary TB involves a combination of four first-line antibiotics: isoniazid, rifampin, ethambutol, and pyrazinamide, typically lasting six to nine months.
Monitoring for adverse effects like hepatotoxicity and peripheral neuropathy is essential throughout treatment. Complications such as multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) necessitate alternative antibiotic regimens, often with longer treatment durations and increased toxicity. Public health interventions, including TB vaccination with Bacillus Calmette-Guérin (BCG), contact tracing, and latent TB infection treatment, are crucial for TB control, alongside collaborative efforts between healthcare providers, public health agencies, and communities to ensure optimal management, reduce morbidity, mortality, and transmission within communities.
Guidelines on the evaluation and management of pulmonary tuberculosis are from the World Health Organization (WHO 2024), the U.S. Preventive Services Task Force (USPSTF 2023), and the Center for Disease Control (CDC/NTCA 2020), among others.
For a full review of pulmonary tuberculosis guidelines, head over to Pathway. We’ll cover some key takeaways below (with the recommendation strength in parentheses).
1) Screening and Diagnosis:
- Obtain screening for latent tuberculosis infection in populations at increased risk. (B)
-
Consider obtaining systematic testing for latent tuberculosis infection in prisoners, health workers, immigrants from countries with a high tuberculosis burden, homeless persons, and persons using drugs. (E)
-
Do not obtain systematic testing for latent tuberculosis infection testing in patients with diabetes, persons engaged in the harmful use of alcohol, persons using tobacco, and underweight persons unless belonging to other risk groups mentioned above. (D)
-
Obtain an IGRA rather than a tuberculin skin test in patients ≥ 5 years old meeting the following criteria:
- likely to be infected with Mycobacterium tuberculosis
- low or intermediate risk of disease progression
-
it has been decided that testing for latent tuberculosis infection is warranted
- history of BCG vaccination or it is expected that the individual is unlikely to return to have the TST read. (A)
2) Diagnostic Investigations:
-
Obtain CXR as first-line imaging in patients with suspected tuberculosis. Obtain CXR in patients with new evidence of exposure or at high risk for the development of tuberculosis, although it may be of low yield in patients with no clinical symptoms. (B)
-
Obtain chest CT if CXR is nonrevealing or nondiagnostic. (B)
-
Consider performing sputum induction rather than flexible bronchoscopic sampling as the initial respiratory sampling method in adult patients with suspected pulmonary tuberculosis if they are unable to expectorate sputum or the expectorated sputum is AFB smear microscopy negative. (C)
-
Obtain AFB smear microscopy in all patients with pulmonary tuberculosis. (A)
-
Obtain Xpert MTB/RIF rather than smear microscopy/culture and phenotypic drug susceptibility testing as an initial diagnostic test for tuberculosis and rifampin resistance detection in sputum in adult patients with signs and symptoms of pulmonary tuberculosis. (B)
3) Medical Management:
- Administer any of the following regimens as the preferred treatment for latent tuberculosis:
-
isoniazid plus rifapentine weekly for 3 months
- rifampin daily for 4 months
- isoniazid plus rifampin daily for 3 months in patients with or without HIV. (B)
-
Include the following agents in longer regimens of patients with MDR-TB/rifampin-resistant tuberculosis:
- levofloxacin or moxifloxacin
- linezolid
-
bedaquiline in patients aged ≥ 18 years. (B)
-
Administer a 6-month regimen of rifampin, ethambutol, pyrazinamide, and levofloxacin for the treatment of patients with confirmed rifampin-susceptible, isoniazid-resistant tuberculosis. Do not add streptomycin or other injectable agents to the treatment regimen. (B)
